Literature DB >> 11126423

Acute and long-term effects of AIDS and injection drug use on gonadal function.

J T Wahlstrom1, A S Dobs.   

Abstract

Hypogonadism has been observed in both the HIV-infected population and injection drug users (IDUs). Considering these populations in conjunction is essential because IDUs and HIV often occur in the same individual. Additionally, although the etiology of hypogonadism may be different in each population, its treatment with respect to the underlying condition is similar. The philosophy of both AIDS and IDU treatment has changed drastically in recent years, due to several factors. Survival rates of HIV patients have been steadily increasing, forcing a closer examination of the long-term effects of AIDS-related symptoms, and the quality of life issues associated therewith. In comparison, IDU is now viewed as a chronic addiction like that for alcoholism, which must be treated, rather than an untreatable personal problem. Therefore, it is logical that the endocrine and metabolic changes associated with both HIV and IDU should be examined to help alleviate these symptoms in a continuing effort to treat the underlying condition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11126423     DOI: 10.1097/00042560-200010001-00005

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  2 in total

1.  Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.

Authors:  Anjali Sharma; Peter L Flom; Jeremy Weedon; Robert S Klein
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

2.  Methadone induces testosterone suppression in patients with opioid addiction.

Authors:  Monica Bawor; Brittany B Dennis; M Constantine Samaan; Carolyn Plater; Andrew Worster; Michael Varenbut; Jeff Daiter; David C Marsh; Dipika Desai; Meir Steiner; Rebecca Anglin; Margaret Coote; Guillaume Pare; Lehana Thabane; Zainab Samaan
Journal:  Sci Rep       Date:  2014-08-26       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.